Literatur
- 1 Council Recommendation. Commission of the European Communities .Proposal for a Council
Recommendation on Cancer Screening. 2003/0093 (CNS). Brussels, 5th of May. 2003
- 2
Davey D D, Armenti C A.
HPV primary screening for cervical cancer: More pain than protection.
Diagn Cytopathol.
2000;
22
333-335
- 3
Herrington C S.
Does HPV testing have a role in primary cervical screening?.
Cytopathology.
2001;
12
71-74
- 4
Petry K U, Menton S, Menton M. et al .
Inclusion of HPV testing in routine cervical cancer screening for women above 29 years
in Germany: Results for 8466 patients.
Br J Cancer.
2003;
88
1570-1577
- 5
Schenck U.
Zytologisches Vorsorgeprogramm - Durch neue Methoden ernsthaft herausgefordert?.
Geburtsh Frauenheilk.
2000;
60
M125-M127
- 6
Schneider A, Scheungraber C, Hoyer H, Dürst M.
Früherkennung des Zervixkarzinoms: Zytologie oder HPV-Test?.
Gynäkologe.
2002;
35
181-192
- 7
Schneider V.
Zervixabstrich noch zeitgemäß?.
Frauenheilkunde plus.
2001;
1
30-33
- 8 Syrjänen K, Syrjänen S. Papillomavirus Infections in Human Pathology. New York;
Wiley 2000: 1-615
- 9
Tempfer C, Leodolter S, Kainz C.
Aktuelle Wertigkeit der HPV-Testung in der klinischen Praxis.
Geburtsh Frauenheilk.
2002;
62
543-549
- 10
Tidy J.
Forgotten implications of HPV positivity for the majority of females: A clinical perspective.
Cytopathology.
2002;
13
263-266
- 11 U. S. Preventive Services Task Force, Screening for Cervical Cancer .AHRQ Publication
No. 03 - 515 A; January 2003. Agency for Healthcare Research and Quality, Rockville,
MD. http:www.ahrq.gov/clinic/3rduspstf/cervicalcan/cervcanrr.htm
.
Prof. Dr. H. F. Nauth
Alexanderstraße 20
70184 Stuttgart
Email: nauth.zyto@tesionmail.de
